Antibody binding specifically to MUC1 and use thereof
US11739159B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2022 |
| Grant date | Aug 29, 2023 |
| Priority date | — |
| Expiry date | Jul 12, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N5/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.